{rfName}
Pr

Altmetrics

Analysis of institutional authors

Cucurull, MAuthor

Share

January 11, 2024
Publications
>
Article
No

Prognostic factors in patients with uterine sarcoma: the SARCUT study

Publicated to: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 33 (6): 897-904 - 2023-06-01 33(6), DOI: 10.1136/ijgc-2022-004204

Authors:

Zapardiel, I; Segovia, MG; Macuks, R; Mancari, R; Achimas-Cadariu, P; Corrado, G; Bartusevicius, A; Sukhin, V; Muruzabal, JC; Martin, PJC; Gardella, B; Piek, JM; Concin, N; Arab, C; Papatheodorou, D; Polterauer, S; Iacoponi, S; Nieto, T; Lopez-Sanclemente, MC; Trukhan, H; Gil, MM; Bakinovskaya, I; Dalamanava, A; Cucurull, M; Rovski, D; Baquedano, L; Chiva, L; Mardas, M; Mavrichev, SA; Klat, J; de la Manzanara, CAL; Yildirim, Y; SARCUT Study Grp
[+]

Affiliations

Catalan Inst Oncol, Lhospitalet De Llobregat, Catalunya, Spain - Author
Catharina Canc Inst, Eindhoven, Netherlands - Author
Catharina Hosp, Gynecol Oncol Dept, Eindhoven, Netherlands - Author
Clin Diatros, Gynecol Oncol Dept, Barcelona, Spain - Author
Clin Univ Navarra, Obstet & Gynecol, Madrid, Spain - Author
Complejo Hosp Navarra, Gynecol Oncol Unit, Pamplona, Navarra, Spain - Author
Fdn IRCCS Policlin San Matteo, Gynecol Oncol Dept, Pavia, Italy - Author
Hosp Clin San Carlos, Gynecol Oncol Unit, Madrid, Comunidad De Ma, Spain - Author
Hosp Gen Univ Ciudad Real, Gynecol Oncol Dept, Ciudad Real, Castilla La Man, Spain - Author
Hosp Univ Miguel Servet, Gynecol Oncol Dept, Zaragoza, Spain - Author
Hosp Univ Santa Cristina, Gynecol Oncol Dept, Madrid, Spain - Author
Innsbruck Med Univ, Dept Gynecol & Obstet, Innsbruck, Austria - Author
IRCCS Regina Elena Natl Canc Inst, Gynecol Oncol Dept, Rome, Italy - Author
IRCCS, Gynecol Oncol Dept, Milan, Italy - Author
Karl Landsteiner Inst Gen Gynecol & Expt Gynecol, Vienna, Austria - Author
Kharkov Natl Univ, Oncol Radiol & Radiat Med, Harkiv, Ukraine - Author
La Paz Univ Hosp, Gynecol Oncol Unit, Madrid, Spain - Author
Lithuanian Univ Hlth Sci, Dept Obstet & Gynaecol, Kaunas, Lithuania - Author
Med Univ Vienna, Comprehens Canc Ctr, Dept Obstet & Gynecol, Div Gen Gynecol & Gynecol Oncol,Gynecol Canc Unit, Vienna, Austria - Author
Metaxa Mem Canc Hosp, Gynecol Oncol Dept, Piraeus, Greece - Author
NAMS Ukraine, Oncogynecol, Grigoriev Inst Med Radiol, Harkiv, Ukraine - Author
NN Alexandrov Natl Canc Ctr, Gynecol Oncol Dept, Minsk, BELARUS - Author
NN Alexandrov Natl Canc Ctr, Gynecol Oncol, Minsk, BELARUS - Author
Oncol Inst Prof Dr Ion Chiricuta Cluj Napoca, Gynecol Oncol Dept, Clu Napoca, Romania - Author
Policlin Univ Agostino Gemelli, Dipartimento Sci Salute Donna & Bambino, Rome, Italy - Author
Poznan Univ Med Sci, Dept Gynecol Oncol, Poznan, Wielkopolskie, Poland - Author
Riga East Clin Univ Hosp, Latvian Oncol Ctr, Riga, Latvia - Author
Tepecik Training & Res Hosp Clin, Gynecol Oncol Dept, Konak, Izmir, Turkiye - Author
Torrecardenas Hosp Complex, Gynecol Oncol Dept, Almeria, Andalucia, Spain - Author
Univ Chile, Hosp Luis Tisne, Gynecol Oncol Dept, Santiago, Chile - Author
Univ Hosp Ostrava, Obstet & Gynecol Dept, , Moravskoslezsky, Ostrava, Czech Republic - Author
See more

Abstract

ObjectiveUterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-free survival of patients with uterine sarcoma. MethodsThis international multicenter retrospective study included 683 patients diagnosed with uterine sarcoma at 46 different institutions between January 2001 and December 2007. ResultsThe 5-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, and adenosarcoma was 65.3%, 78.3%, 52.4%, and 89.5%, respectively, and the 5-year disease-free survival was 54.3%, 68.1%, 40.3%, and 85.3%, respectively. The 10-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma and adenosarcoma was 52.6%, 64.8%, 52.4%, and 79.5%, respectively, and the 10-year disease-free survival was 44.7%, 53.3%, 40.3%, and 77.5%, respectively. The most significant factor associated with overall survival in all types of sarcoma except for adenosarcoma was the presence of residual disease after primary treatment. In adenosarcoma, disease stage at diagnosis was the most important factor (hazard ratio 17.7; 95% CI 2.86 to 109.93). ConclusionIncomplete cytoreduction, tumor persistence, advanced stage, extra-uterine and tumor margin involvement, and the presence of necrosis were relevant prognostic factors significantly affecting overall survival in uterine sarcoma. The presence of lymph vascular space involvement and administration of adjuvant chemotherapy were significantly associated with a higher risk of relapse.
[+]

Keywords

AdenosarcomaAdjuvant chemotherapyAdultArticleCancer prognosisCancer recurrenceCancer stagingCancer surgeryCisplatinClinical trialControlled studyCytoreductionDisease free survivalEndometrial neoplasmsEndometrium sarcomaEndometrium tumorFemaleFollow upHumanHumansKaplan meier methodLeiomyosarcomaLymphadenectomyMajor clinical studyManagementMiddle agedMinimal residual diseaseMulticenter studyNeoplasm recurrence, localOverall survivalPathologyPelvic neoplasmsPelvis tumorPopulationPrognosisRadiotherapyRetrospective studiesRetrospective studyRisk factorSarcomaSarcoma, endometrial stromalStage-iTamoxifenTherapyTumor recurrenceUterine cancerUterine neoplasmsUterus sarcomaUterus tumor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 11/136, thus managing to position itself as a Q1 (Primer Cuartil), in the category Obstetrics & Gynecology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 5.23. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 4.55 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-05, the following number of citations:

  • WoS: 15
  • Scopus: 15
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 11.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 11 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Austria; Chile; Czech Republic; Greece; Italy; Latvia; Lithuania; Netherlands; Oman; Poland; Turkey; Ukraine.

[+]